The David H. Koch Institute for Integrative Cancer Research at MIT
Science + Engineering... Conquering Cancer Together
TRANSCEND is a partnership between the Koch Institute and Ortho-McNeil-Janssen Pharmaceuticals, Inc. Our initial five-year collaborative agreement fosters oncology research and technology development in the areas of cancer diagnostics, cancer biology pre-malignancies, genetic models of disease, and profiles of the tumor microenvironment.
A Joint Scientific Steering Committee composed of MIT faculty members and Ortho-McNeil Janssen employees jointly reviews and selects proposals from MIT researchers for funding. In addition, there is a provision for visiting scientists from Ortho-McNeil Janssen to participate in projects within the investigators’ laboratories at the Koch Institute.
